(NASDAQ:SCYX) is trading up by 5.50% percent from yesterday’s close and has one of the biggest price gains of the day. So far 239,190 shares have changed hands.
The stock last traded at $2.30 impressively higher than the 50 day moving average of $1.84 and a great deal higher than the 200 day moving average of $2.08. The 50 day moving average went up by +24.76% whereas the 200 day average was up by +10.47%.
Investors are feeling more bullish on SCYNEXIS, Inc. recently if you take a look at the motion in short interest. The stock realized a fall in short interest from August 15, 2017 to August 31, 2017 of -10.39%. Short interest decreased 204,206 over that period. The short-interest ratio decreased to 4.0 and the short interest percentage is 0.07% as of August 31.
Here is a rundown on some insider market activity for SCYNEXIS, Inc. (NASDAQ:SCYX). CEO Marco Taglietti purchased 5,000 shares at a price of $1.73 on Wed the 23rd. The CEO now owns $505,160 of the stock per an SEC filing yesterday.
A few notable investment firms have updated their holdings. As of quarter end Iguana Healthcare Management, LLC had disposed of 75,000 shares trimming its position 25.0%. The value in dollars went from $828,000 to $403,000 a change of 51.3% quarter over quarter. As of the end of the quarter Ubs Group Ag had bought a total of 2,110 shares growing its stake by 51.8%. The value of the investment in (SCYX) decreased from $11,000 to $11,000 decreasing 0.0% quarter to quarter.
As of quarter end Ft Options LLC had disposed of 173,931 shares trimming its holdings by 94.6%. The value of the investment in SCYNEXIS, Inc. decreased from $508,000 to $2,000 a change of $506,000 for the reporting period. Kcg Holdings, Inc. reduced its position by selling 44,734 shares a decrease of 29.7%. Kcg Holdings, Inc. owns 105,998 shares valued at $190,000. The total value of its holdings decreased 54.3%.
In the latest earnings report the EPS was $-0.96 and is estimated to be $-1.11 for the current year with 26,722,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.36 and the next full year EPS is projected to be $-1.36.
SCYNEXIS, Inc., launched on November 4, 1999, is a pharmaceutical company, which is involved in the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. It also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. Candida and Aspergillus species are the fungi responsible for all invasive fungal infections in the United States and Europe. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078..